OAC
IMVT icon

OMERS Administration Corp’s Immunovant IMVT Stock Holding History

OMERS Administration Corp’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-48,300
Closed -$825K – 986
2025
Q1 		$825K Buy
+48,300
New +$1.01M 0.01% 610

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

OMERS Administration Corp's IMVT Position: Q2 2025 in Review

OMERS Administration Corp sold out of Immunovant (IMVT) in Q2 2025, closing a stake of 48,300 shares — an estimated $825K sold.

OMERS Administration Corp first reported a position in IMVT in Q1 2025 and held it in 1 quarter. The position peaked at $825K in Q1 2025. 168 funds tracked by Wall St. Rank hold IMVT as of Q2 2025.

  • OMERS Administration Corp reported no remaining Immunovant position as of Q2 2025 after selling out during the quarter.
  • OMERS Administration Corp sold 48,300 Immunovant shares in Q2 2025, an estimated $825K.
  • OMERS Administration Corp first reported a position in Immunovant in Q1 2025 and held it in 1 quarter.
  • OMERS Administration Corp's Immunovant position peaked at $825K in Q1 2025.
  • 168 funds tracked by Wall St. Rank held Immunovant as of Q2 2025.

Based on OMERS Administration Corp's 13F filing for Q2 2025, filed 13 Aug 2025.